鱼精蛋白对耐氨苄青霉素的大肠杆菌作用的初步实验报告

本实验方法为纸片测定耐药菌敏感度法，分为三组（Ａ，氨苄青霉素，Ｂ．鱼精蛋白组，Ｃ氨苄青霉素十鱼精蛋白组）进行观察，结果显示；１、２组制菌环均小于８ｃｍ，第３组中鱼精蛋白浓度大于５００ｕｇ时，制菌环直径大于２０ｃｍ（高度敏感），表明鱼精蛋白在一定浓度下协同氨苄青霉素对耐药的大肠杆菌有效。其作用机理有待进一步研究。     

URODYNAMIC EVALUATION IN THE MANAGEMENT OF THE SPINAL INJURY PATIENT

A practical method of urodynamic evaluation in the patient with a spinal injury, using a slow-filling percutaneous cystometrogram, is described. Cases illustrating the uses of the system and its advantages over clinical assessments of bladder function are presented.     

63例肝外伤预后因素分析

目的 探讨肝外伤的预后因素。方法 回顾性分析1999年1月～2003年5月我院收治的63例肝外伤病例,将患者入院时的10项指标,肝外伤分级标准以及出血量与预后之间关系进行多因素回归分析。结果 患者受伤至就诊时间、收缩压、心率、出血量、肝脏损伤分级和是否合并伤是影响肝外伤预后的主要因素。结论 对影响肝外伤预后的因素应当给予重视,以提高肝外伤的救治率。     

人血管内皮细胞生长因子cDNA克隆和在大肠杆菌的高效表达

目的 在大肠杆菌高效表达人血管内皮生长因子蛋白质。方法 用PCR从人胎儿脑cDNA文库扩增血管内皮细胞生长因子（VEGF）cDNA,得到517bp的DNA片段。扩增片段重组到M13mP18中,经测序证实为VEGF165cDNA。将该片段重组到PRL621温控表达质粒中,在大肠杆菌表达20kd的重组蛋白。结果 该表达产物占菌体总蛋白的35%,其N-端15个氨基酸序列与天然VEGF165蛋白相应序列一致。结论 工程菌TG1/PRL621/VEGF高效表达人VEGF165蛋白质。     

化学去细胞法对粗大神经质量评价方法及影响因素的探讨

目的 通过对粗大神经去细胞方法的研究，探讨对去细胞神经评价和制备的适宜方法。方法 取杂种犬3只，切取5段直径6mm的新鲜坐骨神经，每段长50mm，在3％ Triton-100和7％脱氧胆酸钠溶液中去细胞处理。实验分为5组：Ⅰ组，去细胞2遍；Ⅱ组，去细胞3遍；Ⅲ组，去细胞4遍；Ⅳ组，神经段两端用4号缝合线结扎后去细胞2遍；Ⅴ组，神经段两端用4号缝合线结扎后去细胞3遍。另设对照为未经处理的新鲜犬坐骨神经。从去细胞程度、基底膜板层素（Laminin）活性、脱髓鞘程度及神经纤维管道完整性4个方面进行评价。结果 所有实验组神经段去细胞完全，Laminin活性保存完好。髓鞘染色评分以Ⅳ组和Ⅴ组最低，纤维管道完整性评分以Ⅰ组和Ⅳ组最佳。综合评价对于粗大神经的去细胞处理方法以Ⅳ组处理方法最佳。结论 化学去细胞的神经脱髓鞘程度与去细胞次数不平行。在去细胞神经的质量控制中，应考虑基底膜Laminin的活性、去细胞、脱髓鞘及结构完整性的程度。对于粗大神经的处理，结扎神经段两端后再行去细胞处理可能是一种较好的方法。     

1425例头面部皮肤病对美容影响的调查分析

目的：了解头面部皮肤病的发病情况和对美容及身心健康的影响。方法：2000年1－6月皮肤科门诊就诊的全部病人。结果：调查9159人,有头面部皮肤病者1425人,占受检病人的15．6％,其中颜面再发性皮炎占第一位,痤疮占第二位,扁平疣占第三位。结论：头面部皮肤病有增多趋势,且影响病人的美容及身心健康。     

THE OPTIMUM DURATION OF SYSTEMIC ANTIBIOTIC ADMINISTRATION IN THE TREATMENT OF EXPERIMENTAL PERITONITIS*

The duration of antibiotic therapy for peritonitis is commonly decided on an empirical basis. There is obvious advantage in determining the shortest, yet most effective, period for such drug therapy. This study Is a comparison of short-course and long-course antibiotic administration following peritonitis produced by experimental rupture of the rabbit appendix.     

344例肾移植的内科经验

对３４４例（３５０例次）肾移植病人资料进行分析，以探讨肾移植内科方面经验。发现１．群体反应性抗体（ＰＲＡ）检查对选择受者有好处；２．对高龄（５０岁以上）、糖尿病受者用小剂量激素；３．用血浆置换加药物治疗加速排斥反应有一定效果；４．继发性红细胞增多症用ｔｈｅｏｐｈｙｌｌｉｎｅ治疗有效。     

URODYNAMIC CHARACTERIZATION OF NONOBSTRUCTIVE VOIDING DYSFUNCTION IN SYMPTOMATIC ELDERLY MEN

PURPOSE: The pathogenesis of lower urinary tract symptoms in men without bladder outlet obstruction has not been well characterized. Therefore, we defined the urodynamic abnormalities associated with symptomatic nonobstructive voiding dysfunction, and determined the relationship between age and type of dysfunction. MATERIALS AND METHODS: Video urodynamic studies of symptomatic men without outlet obstruction were examined. The criterion for a normal bladder outlet was a pressure gradient across the prostatic urethra of 5 cm. water or less in the absence of distal stricture. A maximum isometric contraction pressure less than 60 cm. water was regarded as impaired detrusor contractility. Detrusor instability was defined as involuntary detrusor contractions during filling or the inability to suppress a detrusor contraction after initiation of flow. Patients were categorized into 4 groups based on the urodynamic findings. RESULTS: Of 193 men (mean age 69.6+/-10.5 years) 40.9% had detrusor instability (group 1), 31.1% had impaired contractility (group 2), 10.8% had detrusor instability and impaired contractility (group 3), and 17.1% were urodynamically normal (group 4). Average patient age was significantly lower in group 4 than all other groups. Bladder capacity was lowest in group 1, and group 3 had the lowest voiding efficiency. Maximum flow rate, bladder compliance and symptom scores were not different among the 4 groups. The prevalence of detrusor instability with and without impaired contractility increased, while the proportion of patients without urodynamic abnormalities decreased with age. Bladder contractility did not correlate with age. CONCLUSIONS: The nonobstructed patient population comprises several groups that are functionally distinct while symptomatically similar. Thus, treatment of nonobstructed cases based on symptoms may lead to inappropriate pharmacological therapy and unsuccessful clinical outcomes.     

BONE-INDUCTIVE EFFICACY OF RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 EXPRESSED IN ESCHERICHIA COLI: AN EXPERIMENTAL STUDY IN RAT MANDIBULAR DEFECTS

Because to our knowledge the efficacy of prokaryotically expressed recombinant human bone morphogenetic proteins (rhBMP) to promote orthotopic osteogenesis has not previously been investigated, our aim was to test the efficacy of rhBMP-2 produced in Escherichia coli to promote bone healing in a standardised experimental bone healing model in rat mandibles. Different doses of rhBMP-2 were delivered in an absorbable collagen sponge carrier, and microporous barrier membranes were placed over half the number of defects in each treatment group, thereby making intraosseous cells the only recruitment source for new osteogenic cells. Results were evaluated by computerised image analysis after 12 and 24 days. The relative efficacy of rhBMP-2 preparations of different purity was also compared. E coli-produced rhBMP-2 stimulated bone healing, but its efficacy was estimated to be about one order of magnitude less than that of rhBMP-2 expressed in eukaryotic cells. We conclude that bacterially expressed rhBMP-2 is osteogenic in vivo, although higher doses will be required than of rhBMP-2 expressed in mammalian cell lines.     

THE STABILITY OF COAGULATION FACTORS IN STORED BLOOD

The complete coagulation profile of citrate phosphate dextrose (CPD) stored blood has been studied during 21 days storage at 4°C. Ten donations were studied at zero, one, seven, 14 and 21 days. One donation contained small clots and was studied separately. Activities of factors I, II, IX, XII or XIII did not deteriorate significantly. Slight, but clinically unimportant deterioration occurred in factors VII, X and XI. There was marked deterioration in activities of factor V, and factor VIII, the levels decreasing from 1.0μ/ml at day zero to 0.51 to 0.30 respectively at day 21. The donation which contained small clots had more marked decreases in factors V and VIII from the first day. The general stability of coagulation factors suggests that even massive blood replacement is unlikely to result in clinically significant coagulation defects.